Five things for pharma marketers to know: Wednesday, January 18, 2017

Share this content:

1. Rep. Tom Price (R-GA), President-elect Trump's pick for secretary of Health and Human Services, is expected answer questions about his position on the Affordable Care Act and his healthcare investments at a confirmation hearing. Senate Democrats Elizabeth Warren (D-MA), Al Franken (D-MN), and Tammy Baldwin (D-WI) signed a letter requesting a delay of today's hearing due to alleged conflicts of interest. (Healthcare IT News)

2. Twenty-two drugmakers, including Pfizer, Novartis, Merck, and GlaxoSmithKline, said in Davos they will invest $50 million to fight non-communicable diseases including cancer in poor countries, as part of a World Bank initiative, over a three-year period. (Reuters)

3. The FDA approved the first generic version of Jazz Pharmaceuticals' Xyrem, which is a treatment for narcolepsy, a type of sleep disorder. The generic is developed by Roxane Laboratories. (Reuters)

4. A European oncologists group is supporting the use of biosimilar versions of cancer drugs that are effective and affordable. Amgen and Allergan's biosimilar of Roche's Avastin is expected to be the first biosimilar cancer drug to receive E.U. approval this year. (Reuters)

5. A former Google executive launched Forward, a medical concierge service that uses artificial intelligence to collect patient data and offers unlimited access to physicians both face-to-face and via the startup's mobile app for a flat monthly fee. The company has venture backing. (WSJ)
Share this content:
Scroll down to see the next article